Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials
Open Access
- 22 March 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 238
Abstract
Proprotein convertase subtilisin/kexin9 monoclonal antibodies (PCSK9-mAb) have been studied intensively to identify their effect in lowering levels of low density lipoprotein cholesterol (LDL-C). However, the applicable target of PCSK9-mAbs remains inconclusive so far. Therefore, this first meta-analysis was carried out to clarify the therapeutic efficacy and safety of PCSK9-mAbs on the potential patients: familial hypercholesterolemia and statin-intolerant patients. All randomized controlled trials that met the search terms were retrieved in multiple databases. Efficacy outcomes included parameter changes from baseline in LDL-C and other lipid levels. Therapeutic safety were evaluated by rates of common adverse events. A total of 15 studies encompassing 4,288 patients with at least 8 weeks duration were selected. Overall, the therapeutic efficacy was achieved with significant reduction in LDL-C, TC, TG, Lp(a), Apo-B versus placebo. The decline in familial hypercholesterolemia patients (−53.28%, 95% CI: −59.88 to −46.68%) was even more obvious than that in statin-intolerant patients (−34.95%, 95% CI: −41.46 to −28.45%). No obvious safety difference was found out in the rates of common and serious adverse events. To conclude, PCSK9-mAb contributes to the decreased level of LDL-C and other lipids in familial hypercholesterolemia and statin-intolerant patients with satisfactory safety and tolerability.Keywords
This publication has 45 references indexed in Scilit:
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant PatientsJAMA, 2012
- Effects of AMG 145 on Low-Density Lipoprotein Cholesterol LevelsJACC, 2012
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJACC, 2012
- Effect of a Monoclonal Antibody to PCSK9 on LDL CholesterolNew England Journal of Medicine, 2012
- Proprotein Convertases in Health and DiseaseNew England Journal of Medicine, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular MortalityJAMA, 2009
- LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL managementJournal of Clinical Lipidology, 2007
- The apoB/apoA‐I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid‐lowering therapy – a review of the evidenceJournal of Internal Medicine, 2006
- RISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATESThe Lancet, 1969